Together, these results proposed that COL8A1 directly interacting with ITGB1 could activate the PI3K-AKT pathway and promote EMT, thereby leading to CRC resistance to oxaliplatin (Fig. 7T). This evidence concerns the gene AKT1 and colorectal carcinoma.